Treatment of Severe Alzheimer's Disease: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Controlled Study
PHASE3CompletedINTERVENTIONAL
Enrollment
415
Participants
Timeline
Start Date
December 31, 2003
Primary Completion Date
September 30, 2007
Study Completion Date
March 31, 2008
Conditions
DementiaAlzheimer Disease
Interventions
DRUG
galantamine hydrobromide
All Listed Sponsors
lead
Janssen Pharmaceutica N.V., Belgium
INDUSTRY
NCT00216593 - Treatment of Severe Alzheimer's Disease: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Controlled Study | Biotech Hunter | Biotech Hunter